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Abstract
Background: Mantle cell lymphoma (MCL) is an aggressive B-non-Hodgkin lymphoma with generally poor outcome.
MCL is characterized by an aberrantly high cyclin D1-driven CDK4 activity. New molecular targeted therapies such as
inhibitors of the ubiquitin-proteasome system (UPS) have shown promising results in preclinical studies and
MCL patients. Our previous research revealed stabilization of the short-lived pro-apoptotic NOXA as a critical
determinant for sensitivity to these inhibitors. It is currently unclear how cyclin D1 overexpression and aberrant CDK4
activity affect NOXA stabilization and treatment efficacy of UPS inhibitors in MCL.
Methods: The effect of cyclin D1-driven CDK4 activity on response of MCL cell lines and primary cells to proteasome
inhibitor treatment was investigated using survival assays (Flow cytometry, AnnexinV/PI) and Western blot analysis of
NOXA protein. Half-life of NOXA protein was determined by cycloheximide treatment and subsequent Western blot
analysis. The role of autophagy was analyzed by LC3-II protein expression and autophagolysosome detection.
Furthermore, silencing of autophagy-related genes was performed using siRNA and MCL cells were treated
with autophagy inhibitors in combination with proteasome and CDK4 inhibition.
Results: In this study, we show that proteasome inhibitor-mediated cell death in MCL depends on cyclin D1-driven
CDK4 activity. Inhibition of cyclin D1/CDK4 activity significantly reduced proteasome inhibitor-mediated stabilization
of NOXA protein, mainly driven by an autophagy-mediated proteolysis. Bortezomib-induced cell death was significantly
potentiated by compounds that interfere with autophagosomal function. Combined treatment with bortezomib and
autophagy inhibitors enhanced NOXA stability leading to super-induction of NOXA protein. In addition to established
autophagy modulators, we identified the fatty acid synthase inhibitor orlistat to be an efficient autophagy inhibitor when
used in combination with bortezomib. Accordingly, this combination synergistically induced apoptosis both in MCL cell
lines and in patient samples.
Conclusion: Our data demonstrate that CDK4 activity in MCL is critical for NOXA stabilization upon treatment with UPS
inhibitors allowing preferential induction of cell death in cyclin D transformed cells. Under UPS blocked conditions,
autophagy appears as the critical regulator of NOXA induction. Therefore, inhibitors of autophagy are promising
candidates to increase the activity of proteasome inhibitors in MCL.
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Background
Mantle cell lymphoma (MCL) is a rare B cell neoplasia
often characterized by an aggressive clinical course, rela-
tively short response to conventional chemotherapy and
frequent relapses [1]. The initial molecular pathogenic
event of this malignancy is the t(11;14)(q13;q32) transloca-
tion leading to juxtaposition of the CCND1 gene (coding
for cyclin D1) to the immunoglobulin heavy chain com-
plex (IgH) gene [2]. Normally, the G1 phase regulator cyc-
lin D1 is not expressed at high levels in normal B cells but
gets overexpressed as a result of this translocation [3]. As
a binding partner and activator of the cyclin-dependent ki-
nases CDK4 and CDK6, cyclin D1 plays a crucial role in
G1-S transition and promotes proliferation by phosphoryl-
ating RB1 and preventing its inhibitory interaction with
the E2Fs [4]. As CDK6 is hardly expressed in MCL cells,
cyclin D1 mainly exerts its functions via CDK4 [5]. In
addition to its role in cell cycle progression, cyclin D1
affects different cellular processes via both CDK4-
dependent and CDK4-independent mechanisms [6]. Cyc-
lin D1/CDK4 activity has also been shown to suppress the
autophagic degradation machinery [7–11].
The proteasome inhibitor bortezomib which was
approved for treatment of relapsed or refractory MCL
was recently included in the first-line treatment of MCL
[12, 13]. As there are still many patients who are poorly
responding to bortezomib treatment, there is urgent
need to elucidate the basis for bortezomib sensitivity
and resistance [12]. Different resistance mechanisms to
bortezomib have been proposed including accumulation
of Bcl-2 protein in lymphoma cells, mutation as well as
overexpression of proteasomal subunits in THP1 cells and
plasmacytic differentiation, elevated nuclear factor-κB
activity, or increased autophagy in MCL cells [14–18].
Combination of bortezomib with substances that target
the DNA methyltransferase, histone acetylation, prosurvi-
val chaperones, PI3K/AKT signaling, or the anti-apoptotic
protein MCL1 have been shown to enhance the efficacy of
bortezomib in MCL [19–23]. Work from our group
revealed that extensive proteasomal degradation of the
pro-apoptotic Bcl-2 family protein NOXA and corre-
sponding low protein levels is crucial for sensitivity of
MCL to the proteasome inhibitor bortezomib [24].
The aim of the present work is to investigate how cyc-
lin D1 overexpression and aberrant CDK4 activity affect
treatment efficacy of bortezomib in MCL. Furthermore,
we seek to elucidate underlying molecular mechanisms




The MCL cell lines Mino, Jeko-1, Rec-1, Jvm2, and
Granta-519 were obtained from the German Collection
of Microorganisms and Cell Cultures GmbH (Germany).
NIH3T3 cells stably transfected with human CD40 lig-
and were a kind gift from Dr. Martina Seiffert from the
German Cancer Research Center, DKFZ (Germany). All
cell lines were tested for mycoplasma contamination and
recently authenticated by short tandem repeat profiling.
Cell lines as well as the primary MCL cells were
cultivated in RPMI-1640 (Biochrom, Germany) supple-
mented with 20% fetal calf serum, 0.1 g/l penicillin-




Spautin-1, orlistat, BEZ235, Cerulenin, and hydrogen
peroxide were purchased from Sigma-Aldrich Chemie
GmbH (Germany). Liensinine was obtained from Chem-
Faces (China) and bortezomib, carfilzomib, and palboci-
clib from Selleck Chemicals (USA).
Protein expression analysis
Cells were lysed, sonicated, and boiled to obtain cellular
proteins according to standard protocols. Western blots
were performed using a SDS-PAGE Gel Electrophoresis
system. Proteins were blotted on Amersham Protran 0.1
NC nitrocellulose membranes, except for LC3 which
was blotted on Amersham Hybond P 0.2 PVDF mem-
branes (GE Healthcare, USA). The primary antibodies
used were anti-NOXA antibody (Calbiochem, USA),
anti-cyclin D1 antibody (Santa Cruz Biotechnology,
USA), anti-MCL1, RB1, β-actin, α-tubulin, ATG5,
ATG7, LC3, CDK4, PUMA, BAX, BAK, and GAPDH
(Cell Signaling, USA).
Autophagolysosome detection
After treatment, samples containing 5 × 105 to 1 × 106
cells were stained with Cyto-ID Green Detection Re-
agent (Enzo Life Sciences, USA) according to manufac-
turer’s instructions for 30 min at 37 °C in the dark.
Afterwards, cells were stained with AnnexinV-APC (BD
Pharmingen, Germany) and subsequently analyzed by
flow cytometry. The Cyto-ID fluorescence intensity of
AnnexinV-APC negative cells was detected and com-
pared by histogram overlays for the different treatments.
mRNA expression analysis
RNA was extracted using RNeasy Mini Kit (QIAGEN N.V.,
Netherlands) and transcribed to cDNA according to stand-
ard protocols. NOXA (PMAIP1) expression was analyzed
using TaqMan Gene Expression Assay Hs00560402_m1
(Applied Biosystems, USA) on 7900 HT Fast Real-Time
PCR System (Applied Biosystems) according to the manu-
facturer’s instructions. TBP (Hs00427620_m1) was used for
normalization of NOXA mRNA expression.
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Gene silencing
For gene silencing, we used siGENOME siRNA Re-
agents - Human SMARTpool siRNA (Dharmacon,
UK). Sequences targeted by the siRNAs are shown in
Additional file 1: Table S1. As control, siRNA (cosi)
non-targeting siRNA#1 (Dharmacon, UK) was used.
For electroporation, the Nucleofector™ II/2B, the Cell
Line Nucleofector® Kit V, and the program X-001
(Lonza Group Ltd., Basel, Switzerland) were used.
Knockdown efficacy was analyzed by Western blot.
Cell death detection
Cell death was assessed by staining the cells with
AnnexinV-FITC (BD Pharmingen, Heidelberg, Germany)
and propidium iodide (PI) (Sigma-Aldrich, Steinheim,
Germany) and subsequent analysis by flow cytometry.
Combination index (CI) values were determined with
the CalcuSyn Software (Biosoft, UK), whose algorithm is
based on the Chou and Talalay’s method [25]. A combin-
ation index smaller than 0.9 indicates a synergistic effect
between two substances.
Measurement of cell cycle distribution
Analysis of cell cycle distribution was carried out using
BrdU staining as previously described [26].
Determination of protein half-life
The half-life of NOXA protein was determined by treat-
ing the cells with 20 μg/ml cycloheximide and harvesting
cell pellets at different time points for subsequent ana-
lysis by Western blot.
Statistics
Data are obtained from at least three independent experi-
ments and expressed as standard deviation (SD) of the
mean. Statistics were calculated using GraphPadPrism 4.0
software (GraphPad Software, La Jolla, CA, USA).
Changes in paired samples were analyzed using two-sided
paired t test, and results were considered statistically sig-
nificant when p < 0.05 (*p < 0.05; **p < 0.01; ***p < 0.001).
Results
Cyclin D1-driven CDK4 activity is required for cell death
and induction of NOXA protein upon proteasome
inhibitor treatment
Sensitivity of MCL cells to inhibitors of the ubiquitin-
proteasome pathway (UPS), such as bortezomib, has been
associated with the BH3 only protein NOXA [24, 27, 28].
A recently published preclinical study also demonstrated a
link between cyclin D1 expression and bortezomib sensi-
tivity in multiple myeloma cell lines [29]. However, it is
not well established if bortezomib sensitivity is dependent
on the kinase activity of the cyclin D1/CDK4 complex and
if NOXA is affected by this activity in MCL cells. To
address this issue, we first incubated MCL cell lines Mino,
Jeko-1, and Granta-519 with or without palbociclib, a po-
tent and selective CDK4/6 inhibitor and co-treated the
cell lines with bortezomib. In all three MCL cell lines in-
vestigated, co-treatment with palbociclib partially rescued
cells from bortezomib-induced cell death (Fig. 1a, left).
Co-treatment of bortezomib with palbociclib led to a re-
duced induction of NOXA protein in the MCL cell lines
and in patient-derived primary MCL cells (Fig. 1a, right).
Importantly, palbociclib treatment inhibited CDK4-
dependent phosphorylation of RB1 in Mino, Jeko-1, and
Granta-519 (Additional file 2: Figure S1). In order to
prevent excessive cell death caused by the extended
cultivation duration during the co-treatment schedule, we
co-cultivated the primary MCL cells with CD40 ligand-
expressing fibroblasts and different cytokines. This re-
sulted in an acquired therapy resistance of the primary
MCL cells which did not exhibit cell death after bortezo-
mib treatment with or without palbociclib co-treatment
(data not shown). The development of therapy resistance
mechanisms after co-culturing primary MCL cells is
known and involves the activation of survival pathways
and the increased expression of anti-apoptotic Bcl-2 fam-
ily proteins [30, 31]. In order to analyze if the antagonism
on the bortezomib effect after palbociclib treatment was
dependent on inhibition of cyclin D1-driven CDK4 activ-
ity, we performed siRNA-mediated knockdown of either
cyclin D1 or CDK4. We observed a comparable reduction
in bortezomib sensitivity in MCL cell lines Mino and
Jeko-1 after knockdown of cyclin D1 or CDK4 (Fig. 1b, left
and Additional file 3: Figure S2). In addition, NOXA
induction after bortezomib treatment was also antago-
nized by knockdown of cyclin D1 or CDK4 (Fig. 1b, right).
Double knockdown of cyclin D1 and CDK4 did not
increase the antagonism on bortezomib-induced cell death
(Additional file 4: Figure S3), indicating that in this con-
text, both of these proteins exert their function through
the same pathways.
Collectively, these data demonstrate that cyclin D1/
CDK4 activity is required for effective accumulation of
NOXA protein and thus also for complete execution of
bortezomib-induced cell death in MCL.
We next asked if inhibition of CDK4 activity might also
reduce sensitivity to other clinically relevant proteasome
inhibitors such as carfilzomib. In contrast to bortezomib,
which not only reversibly blocks the chymotrypsin- and
caspase-like activity of the proteasome but also binds dif-
ferent serine proteases, carfilzomib is more specific and
irreversibly binds the N-terminal threonine active sites of
the proteasome [32, 33]. As shown in Fig. 1c, the effect of
palbociclib on carfilzomib-induced cell death and NOXA
accumulation in MCL cell line Mino was identical to that
observed with bortezomib. Importantly, this could also be
shown for other compounds which have been identified to
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be effective in MCL cells via upregulation of NOXA, such
as the fatty acid synthase inhibitor orlistat (Fig. 1c; [24]) as
well as for hydrogen peroxide (Fig. 1c; [34]). Similar
results were also observed in the MCL cell line Jeko-1
(Additional file 5: Figure S4). In order to confirm that the
inability to induce cell death after co-treatment of borte-
zomib with palbociclib is dependent on NOXA, we per-
formed knockdowns of NOXA and its anti-apoptotic
binding partner MCL1. NOXA knockdown rescued
bortezomib-induced cell death (Fig. 1d). Furthermore,
knockdown of MCL1 reversed the palbociclib-mediated
antagonism on bortezomib-induced cell death, whereas
NOXA knockdown further increased the antagonism on
cell death induction (Fig. 1d).
Together, these observations indicate that cyclin
D1-driven CDK4 activity is required for effective
upregulation of NOXA and concomitant induction of
cell death not only upon treatment with proteasome
inhibitors but also other NOXA protein inducing
agents.
Inhibition of CDK4 activity antagonizes proteasome
inhibitor-mediated stabilization of NOXA by autophagy-
driven proteolysis
Previous studies have shown that inhibition of the prote-
asome leads to induction of NOXA transcript [28, 35].
However, the predominant mechanism by which NOXA
protein is enhanced seems to be protein stabilization by
targeting the rapid NOXA protein turnover both in MCL
and in melanoma cells [24, 36]. To uncover the mechan-
ism by which CDK4 inhibition diminishes NOXA protein
in bortezomib-treated cells, we first quantified NOXA
RNA levels. We found only minor differences of NOXA
transcript induction upon bortezomib in cells pre-incu-
bated with or without palbociclib, indicating that tran-
scriptional regulation of NOXA upon bortezomib is not
the predominant effect of CDK4 inhibition on NOXA
regulation (Additional file 6: Figure S5). Palbociclib
antagonism on bortezomib-induced cell death might also
be mediated by alterations in cell cycle distribution. We
therefore performed a knockdown of RB1 to allow cells to
progress to s-phase while CDK4 is inhibited. Even though
cells progressed to s-phase (Additional file 7: Figure S6,
left panel), palbociclib antagonized bortezomib-induced cell
death in RB1 knockdown cells in the same extent as cells
transfected with control siRNA (Additional file 7: Figure S6,
middle panel). Furthermore, bortezomib treatment led to a
similar decrease of s-phase cells as palbociclib treat-
ment (Additional file 7: Figure S6, left panel).
Consequently, we conclude that it is unlikely that cell
cycle distribution does mediate palbociclib effects on
bortezomib-induced cell death.
We therefore studied NOXA protein stability using cy-
cloheximide pulse-chase experiments. In accordance
with previous studies [24, 37], bortezomib significantly
prolonged NOXA half-life in MCL cell line Mino
(Fig. 2a), whereas palbociclib alone had no effect on
NOXA protein stability. Interestingly, the stabilizing
effect of bortezomib was almost completely antagonized
when co-treated with palbociclib indicating that CDK4
inhibition activates a proteasome-independent degrad-
ation of NOXA.
Several groups have shown that CDK4 activity [7–11]
can suppress autophagy, which represents another central
degradation mechanism delivering cytosolic proteins, ag-
gregates, or organelles to lysosomes [38]. In line with this,
we observed an increase of the autophagy marker LC3-II
in MCL cell line Mino upon co-treatment of bortezomib
with palbociclib or after treatment with palbociclib alone
(Fig. 2b, upper panel). LC3-II protein levels can be ele-
vated either because the completion of autophagy is
impaired which leads to an accumulation of autophago-
somes or because there is an actual increase of the
autophagic flux [39]. To differentiate this, we treated the
MCL cell line Mino with palbociclib and the down-
stream autophagy inhibitor hydroxychloroquine which
(See figure on previous page.)
Fig. 1 Cyclin D1-driven CDK4 activity is required for cell death induction of NOXA accumulating agents. a CDK4 inhibition by palbociclib
antagonizes bortezomib-induced cell death and NOXA accumulation. MCL cell lines Jeko-1 and Granta-519 were treated with 300 nM and Mino
with 100 nM palbociclib for 16 h and subsequently co-treated with 8 nM bortezomib for 24 h. Primary MCL cells were exposed to 50 ng/ml
interleukin-10, 50 ng/ml B cell activating factor, 1 ng/ml of insulin-like growth factor-1, 1 ng/ml interleukin-6, and co-cultured with the CD40
ligand-expressing cell line 3T3. After 8 h of co-culture, cells were treated with 300 nM palbociclib for 16 h and subsequently co-treated with
10 nM bortezomib. The 3T3 cell line was irradiated with 30 Gy 1 day before co-culture. After 8 h, protein expression was analyzed (right), and
after 24 h, cell death was assessed by AnnexinV-PI staining (left). b Knockdown of cyclin D1 and CDK4 antagonizes bortezomib-induced cell
death and NOXA accumulation. MCL cell line Mino was transfected with siRNA targeting CCND1 and CDK4. Twenty-four hours after transfection,
cells were treated with 8 nM bortezomib. After 8 h, protein expression was analyzed (right) and cell death was assessed by AnnexinV-PI staining
(left) 24 h post-treatment. c CDK4 inhibition antagonizes cell death of NOXA inducing substances and NOXA accumulation. MCL cell line Mino
was treated with 100 nM palbociclib for 16 h and subsequently co-treated with either 8 nM carfilzomib, 20 μM orlistat, or 500 μM hydrogen
peroxide. After 8 h, protein expression was analyzed (right), and after 24 h, treatment cell death was assessed by AnnexinV-PI staining (left). d
MCL cell line Mino was transfected with siRNA targeting PMAIP1 and MCL1 and treated with 100 nM palbociclib. Twenty-four hours after transfection,
protein expression was analyzed (right) and cells were treated with 8 nM bortezomib. Cell death was assessed by AnnexinV-PI staining 24 h post-treatment
(left). Data represent means ± S.D. from three independent experiments
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inhibits the acidification of lysosomes, completely
blocks autophagy in its final step and therefore leads
to the accumulation of autophagosomes [40]. Hydro-
xychloroquine treatment induced LC3-II protein levels
which, importantly, were further increased by co-
treatment with palbociclib (Fig. 2b, middle panel). We
can thereby conclude that inhibition of CDK4 activity
results in increased autophagic flux. In addition,
direct staining of autophagic vacuoles with the au-
tophagy Cyto-ID Green dye and subsequent cytomet-
ric analysis corroborated our results that we obtained
by analyzing LC3-II protein expression. CDK4 inhibition
with palbociclib alone or after co-treatment with bortezo-
mib induced an increase in green fluorescence, indicative
of elevated levels of autophagic vesicles (Fig. 2b, lower
panel). Similar results were observed in MCL cell line
Jeko-1, where palbociclib treatment led to an increase in
green fluorescence (Additional file 8: Figure S7A).
Furthermore, co-treatment of palbociclib with hydroxy-
chloroquine showed higher green fluorescence than hydro-
xychloroquine alone (Additional file 8: Figure S7A),
corroborating our result that CDK4 inhibition results in in-
creased autophagic flux (Fig. 2b, middle panel). Short-term
treatment of MCL cell line Mino with Palbociclib, however,
did not led to an increase in autophagic vacuoles (Add-
itional file 8: Figure S7B), indicating that it requires more
time to activate intermediate signals that induce autophagy.
To test whether the antagonizing effect of palbociclib
on bortezomib-induced NOXA stability is mediated by
activating an autophagy-lysosome pathway (ALP)-depen-
dent degradation of NOXA, we performed RNAi-medi-
ated knockdowns of autophagy-related proteins (ATG5/
7) and investigated NOXA protein stability. Indeed,
compared to control siRNA genetic blockade of autoph-
agy by pre-incubation with ATG5/7 siRNA prolonged
NOXA half-life in the MCL cell line Mino co-treated
with palbociclib (Fig. 2c), reaching a protein stability
comparable to that observed in cells treated with
bortezomib alone (Fig. 2a). Importantly, in cells
co-treated with palbociclib, genetic or pharmacologic in-
hibition of autophagy with Spautin-1, liensinine, or
3-methyladenine (3-MA) also restored the effect of bor-
tezomib on cell death induction in MCL cell lines Mino
and Jeko-1 (Fig. 2d, left and Additional file 9: Figure S8)
and on NOXA induction in MCL cell line Mino (Fig. 2d,
right). These results indicate that inhibition of CDK4
antagonizes bortezomib efficacy via an autophagy-medi-
ated degradation of NOXA.
Inhibition of autophagy synergizes with bortezomib-
induced cell death and NOXA stabilization in MCL
If NOXA stability is targeted by UPS and ALP-mediated
proteolysis, we would expect an enhanced half-life of
NOXA upon inhibition of both the proteasome and the
autophagy pathway as well as an increase of cell death as
compared to proteasome inhibition alone. To address
this issue, we used a cell line with reduced sensitivity to
proteasome inhibitors, namely Jeko-1 (Fig. 1), and per-
formed cycloheximide pulse-chase experiments. For
evaluation of NOXA protein stability, cells were
incubated in presence or absence of the UPS inhibitor
bortezomib, the autophagy inhibitor 3-MA, and the
combination of both. Interestingly, inhibition of autoph-
agy alone had no effect on NOXA protein half-life
(Fig. 3a) indicating that ALP has a minor role for NOXA
degradation in cells with active UPS. However, compared
to inhibition of the proteasome alone, combined
inhibition of the ubiquitin-proteasome and the
autophagy-lysosome pathways led to a significant
(See figure on previous page.)
Fig. 2 Proteasome inhibitor-mediated stabilization of NOXA is abrogated through an autophagy-driven proteolysis. a Increased half-life of Noxa
protein after bortezomib treatment is diminished after palbociclib co-treatment. MCL cell line Mino was treated with 100 nM palbociclib for 16 h
and subsequently co-treated with 8 nM bortezomib. After 8 h co-treatment, 20 μg/ml cycloheximide was added to the cells and samples were
harvested 0, 15, 30, 45, 60, and 90 min after cycloheximide exposition for Western blot analysis. b Palbociclib treatment induces autophagy. MCL
cell line Mino was treated with 100 nM palbociclib for 16 h and subsequently co-treated with 8 nM bortezomib. After 8 h, protein expression was
analyzed (upper panel). MCL cell line Mino was treated with 40 μM hydroxychloroquine and 100 nM palbociclib for 16 h and subsequently co-treated
with 8 nM bortezomib. After 8 h, protein expression was analyzed (middle panel). MCL cell line Mino was treated with 40 μM hydroxychloroquine for
24 h or treated with 100 nM palbociclib for 16 h and subsequently co-treated with 8 nM bortezomib for 24 h. After treatment, autophagic vesicles
were measured by Cyto-ID staining (lower panel). c Knockdown of autophagy-related genes reverses the palbociclib-mediated antagonism
on bortezomib-mediated stabilization of NOXA. MCL cell line Mino was transfected with siRNA targeting ATG5 and ATG7. Twenty-four hours after
transfection, cells were treated with 100 nM palbociclib for 16 h and subsequently co-treated with 8 nM bortezomib. After 8 h, cells were exposed to
20 μg/ml cycloheximide and samples were harvested 0, 15, 30, 45, 60, and 90 min after cycloheximide addition and analyzed by Western blot. d
Knockdown of autophagy-related genes as well as autophagy inhibitors counteract palbociclib-mediated antagonism on bortezomib-induced cell
death and NOXA induction. MCL cell line Mino was transfected with siRNA targeting ATG5 and ATG7. Twenty-four hours after transfection, cells were
treated with 100 nM palbociclib for 16 h and subsequently co-treated with 8 nM bortezomib. After 8 h, protein expression was analyzed (upper right)
and cell death was assessed by AnnexinV-PI staining 24 h post-treatment (upper left). MCL cell line Mino was treated with 100 nM palbociclib and
20 μM liensinine (upper middle panel), 5 μM Spautin-1 (lower middle panel), or 2 mM 3-MA (lower panel) for 16 h and subsequently co-treated with
8 nM bortezomib. After 8 h, protein expression was analyzed (right) and cell death was assessed by AnnexinV-PI staining 24 h post-treatment (left).
Data represent means ± S.D. from three independent experiments
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increase of NOXA stability as shown by Western blot
analysis (Fig. 3a, upper panel) and corresponding densi-
tometric quantification (Fig. 3a, lower panel). Import-
antly, this elevated NOXA accumulation upon combined
inhibition of autophagy and proteasome was accompan-
ied by a significantly enhanced cell death as compared
to proteasome inhibition alone (Fig. 3b, lower panel).
Analogous to the results obtained with 3-MA, combin-
ation of bortezomib with the autophagy inhibitors liensi-
nine or hydroxychloroquine also resulted in an elevated
NOXA accumulation as well as enhanced cell death
compared to proteasome inhibition alone (Fig. 3b). In
line with this, autophagy inhibitors also potentiated
bortezomib-induced cell death in another bortezomib-
resistant cell line, namely Rec-1 (Additional file 10:
Figure S9).
Together, these results indicate that bortezomib-medi-
ated accumulation of NOXA is partially hampered by a
parallel degradation of NOXA via autophagy. Therefore,
combined inhibition of both UPS and autophagy poten-
tiates both stabilization of NOXA protein and induction
of cell death in MCL cells.
Orlistat acts synergistically with bortezomib to
accumulate NOXA and induce potent cell death in MCL
cells
Previous work of our group showed that MCL cells can
be efficiently treated using the fatty acid synthase inhibi-
tor (FASNi) orlistat [24, 41]. This cell death relies on the
efficient stabilization of NOXA protein. The FASNi orli-
stat has been shown to block palmitate synthesis [42].
Interestingly, many studies have shown that palmitate
levels are linked to ER stress and autophagy regulation
[43–45]. Therefore, we investigated if bortezomib effects
could be potentiated by orlistat co-treatment in analogy
to the observation with autophagy inhibitors (Fig. 3).
Co-treatment of bortezomib with the fatty acid inhibi-
tor orlistat led to a blockade of autophagic degradation
in MCL cell line Mino (Fig. 4a), which is characterized
by an elevated LC-3 II protein expression and a
concomitant accumulation of the P62 protein which is
exclusively degraded by autophagy [46]. Consequentially,
orlistat prolonged bortezomib-mediated NOXA half-life
in bortezomib-resistant cell line Jeko-1 as shown by West-
ern blot analysis (Fig. 4b, upper panel) and corresponding
Fig. 3 Autophagy inhibitors potentiate bortezomib-induced cell death through NOXA stabilization. a Co-treatment of bortezomib with an autophagy
inhibitor potentiates half-life increase of NOXA protein. MCL cell line Jeko-1 was treated with 2 mM 3-MA for 16 h and subsequently co-treated with
7 nM bortezomib. After 14 h, 20 μg/ml cycloheximide was added to the cells and samples were harvested 0, 30, 45, 60, 90, and 120 min
after cycloheximide exposition for Western blot analysis (upper panel) and corresponding densitometric analysis of NOXA protein stability
(lower panel). b Co-treatment of Bortezomib with autophagy inhibitors potentiates cell death induction as well as NOXA protein accumulation. MCL
cell line Jeko-1 was treated with 20 μM liensinine, 40 μM hydroxychloroquine, or 2 mM 3-MA for 16 h and subsequently co-treated with 8 nM bortezomib.
After 8 h, protein expression was analyzed (upper panel), and after 24 h treatment, cell death was assessed by AnnexinV-PI staining (lower panel). Data
represent means ± S.D. from three independent experiments
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Fig. 4 FASNi modulates autophagy upon proteasome inhibition and leads to synergistic cell death in MCL cells. a Co-treatment of bortezomib
with the fatty acid synthase inhibitor orlistat blocks autophagy. MCL cell line Mino was treated with 15 μM orlistat and 7 nM bortezomib. After
8 h, samples were harvested for Western blot analysis. b Inhibition of proteasome and fatty acid synthase further increases NOXA half-life. MCL
cell line Jeko-1 was treated with 15 μM orlistat and 7 nM bortezomib. After 14 h, 20 μg/ml cycloheximide was added to the cells and samples
were harvested 0, 30, 45, 60, 90, 120, and 180 min after cycloheximide exposition for Western blot analysis (upper panel) and quantification of
NOXA protein stability (lower panel). c Co-treatment of bortezomib with orlistat induces cell death in MCL cell lines. MCL cell lines were treated
with 15 μM orlistat and 7 nM (Jeko-1 and Rec-1) or 5 nM (Mino and Jvm2) bortezomib. After 14 h, protein expression was analyzed (Jeko-1), and
after 24 h, cell death was assessed by AnnexinV-PI staining. d Co-treatment of bortezomib with orlistat induces cell death in primary MCL cells.
Primary MCL cells were treated with 15 μM orlistat and 7 nM (four patients, upper panel) or 5 nM (six patients, lower panel) bortezomib. After
24 h, samples were taken for Western blot analysis (left) and cell death was assessed by AnnexinV-PI staining (right). e Healthy lymphocytes and
monocytes are hardly affected by co-treatment of proteasome inhibitors with orlistat. Peripheral blood mononuclear cells were treated with
15 μM orlistat and 5 nM or 7 nM bortezomib. After 24 h, cell death was assessed by AnnexinV-PI staining. Data represent means ± S.D. from three
independent experiments
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densitometric quantification (Fig. 4b, lower panel). This
enhanced protein stability resulted in super-induction of
NOXA protein and an almost complete loss of viability in
four MCL cell lines characterized by different sensitivity to
bortezomib monotherapy (Fig. 4c). The same results were
obtained with carfilzomib (Additional file 11: Figure S10)
indicating that the potentiating effect was not due to a dif-
ferential bortezomib uptake or substance cross-interaction.
Changes in expression levels of other apoptotic proteins
apart from NOXA after combination treatments were not
observed (Additional file 12: Figure S11). Treatment of
the MCL cell line Jeko-1 with different combinations of
orlistat and bortezomib or carfilzomib resulted in syner-
gistic cell death even at low concentrations of bortezomib
and carfilzomib (Additional file 13: Figure S12). Cell death
induced by these combinations was dependent on caspase
activity and could be blocked by pre-incubation with the
pan-caspase inhibitor Z-VAD-FMK (Additional file 11:
Figure S10). Importantly, similar effects were also ob-
served in patient-derived primary MCL cells. Combination
of orlistat together with bortezomib led to an enhanced
NOXA protein expression and significantly potentiated
the cytotoxic effect of bortezomib alone (when applied at
7 nM; Fig. 4d upper panel). Even a low bortezomib con-
centration of 5 nM which had only minor effects in mono-
therapy led to a significant increase of cell death when
combined with orlistat (Fig. 4d, lower panel). Of note, this
combinatory treatment had only minor effects on periph-
eral blood mononuclear cells (PBMNC) from healthy
donors (Fig. 4e).
Collectively, these data demonstrate that the combin-
ation of bortezomib with a FASNi provides a potent tool
to effectively induce MCL cell death via super-induction
of NOXA presumably by parallel inhibition of the prote-
asome as well as the autophagic degradation machinery.
Effective stabilization of NOXA and concomitant
induction of apoptosis in MCL cells requires cyclin D1-
CDK4 activity
After demonstrating that cyclin D1-CDK4 activity is
important for response to bortezomib in MCL cells
(Fig. 1), we next asked if this also holds true for the
more effective combination of bortezomib with orlistat.
Indeed, knockdown of cyclin D1 or CDK4 in MCL cell
line Jeko-1 blocked accumulation of NOXA upon com-
binatory treatment as effective as direct NOXA knock-
down (Fig. 5a). Analogous to bortezomib alone,
pharmacological inhibition of CDK4 by palbociclib prior
to combination treatment was sufficient to abrogate
NOXA accumulation (Fig. 5b). Again, consistent with
the effects observed in cells treated with bortezomib
alone, genetic or pharmacologic blockade of cyclin D1/
CDK4 also partially rescued the more effective apoptosis
upon co-treatment with orlistat.
Fig. 5 CDK4 activity is required for cell death induction after combined fatty acid synthase and proteasome inhibition. a Knockdown of either
cyclin D1 or CDK4 antagonizes cell death as well as NOXA protein induction as efficient as knockdown of NOXA. MCL cell line Jeko-1 was transfected
with siRNA targeting NOXA, CCND1, and CDK4. Twenty-four hours after transfection, cells were treated with 15 μM orlistat and 7 nM bortezomib. After
14 h, protein expression was analyzed (right) and cell death was assessed by AnnexinV-PI staining (left) 24 h post-treatment. b Co-treatment of bortezomib
with orlistat is antagonized by palbociclib treatment. MCL cell line Jeko-1 was treated with 300 nM palbociclib and subsequently co-treated with 15 μM
orlistat and 7 nM bortezomib. After 14 h, protein expression was analyzed (right) and cell death was assessed by AnnexinV-PI staining (left). Data represent
means ± S.D. from three independent experiments
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Together, these results demonstrate that effective
NOXA accumulation and induction of cell death after
combined proteasome and fatty acid synthase inhibition
is dependent on cyclin D1/CDK4 activity in MCL cells.
Discussion
In MCL stabilization of the short-lived pro-apoptotic
BH3-only protein, NOXA is a major determinant for its
sensitivity to bortezomib and other therapeutics [24, 28].
Our results show that the aberrant cyclin D1/CDK4
activity in MCL is critical for NOXA protein induction
and thereby directly contributes to cell death triggered
by proteasome inhibition. Similar to MCL, in multiple
myeloma, cyclin D1 overexpression is also frequently ob-
served and the disease is responding well to proteasomal
inhibition [47, 48]. Interestingly, the susceptibility to
bortezomib was also shown to be dependent both on
cyclin D1 and on NOXA protein expression [29, 49]. In
addition, a correlation between cyclin D1 overexpression
and response to bortezomib treatment was also shown
in breast cancer [50]. We show that in MCL, both in-
duction of NOXA protein and cell death by bortezomib
are largely abolished when CDK4 activity is blocked by
pharmacologic inhibition or genetic manipulation. Fur-
thermore, our experiments clarify that autophagy is the
biological mechanism underlying the interaction be-
tween proteasome inhibition and CDK4 activity in the
regulation of cell death in MCL cells. When MCL cells
are exposed to bortezomib, NOXA can only be effi-
ciently induced if the aberrant cyclin D1/CDK4 activity
inhibits autophagy. This allows the very efficient induc-
tion of NOXA protein and explains the preferential sen-
sitivity of cyclin D1 transformed cells to bortezomib.
The autophagy-lysosomal degradation pathway is known
to be suppressed by cyclin D1/CDK4 activity [8–10]. The
exact mechanism of how autophagy and CDK4 activity is
linked in MCL remains to be determined. It has recently
been reported that autophagy triggered by CDK4 inhibition
relies on the induction of reactive oxygen species (ROS) [9].
Other reports identified AMPK signaling as a link between
CDK4 activity and autophagy, as AMPK can directly phos-
phorylate the autophagy activating kinase ULK1 or inhibit
the mTOR pathway which again blocks autophagy by inhi-
biting ULK1 [51–53]. Of note, the mTOR inhibitor Everoli-
mus has been shown to induce autophagy in MCL [54]. In
line with these data, we also observed an antagonism on
bortezomib-induced cell death by the dual PI3K/mTOR in-
hibitor BEZ235 as well as by the AMPK activator metfor-
min (data not shown).
We show for the first time that in the absence of
proteasomal activity, NOXA can be degraded by the
autophagy-lysosome pathway. Many proteins are de-
graded by both autophagosome and the proteasome
[55]. Proteasomal degradation of NOXA has been
extensively studied [56]. It is known that proteasome
inhibition may reveal a crosstalk between the ubiquitin-
proteasome system and the autophagy-lysosomal path-
way enabling a so-called compensatory autophagy [57].
Whether NOXA can be directed to the autophagosomal
degradation machinery has never been described.
Chaperone-mediated autophagy (CMA) is a selective
catabolic pathway that mediates proteins to lyso-
somes. This pathway involves specific chaperones, the
lysosome-associated membrane protein type 2A
(LAMP-2A) and the presence of a peptide motif bio-
chemically related to KFERQ [58]. As this motif is
mandatory for CMA and as it is not present in the
NOXA protein sequence, it is unlikely that NOXA is
a target for CMA. Macroautophagy (generally referred
to as autophagy), however, involves proteins of the
ATG8 family which promote the entry of cargo recep-
tors into the autophagy pathway through interaction
with the LC3-interacting regions (LIR) [59]. Interest-
ingly, a LIR motif can be found in the NOXA protein
sequence (Additional file 14: Figure S13) and might
therefore target NOXA for ALP-dependent proteolysis.
Our findings have important implications for further
development of combinatorial strategies with proteaso-
mal inhibitors. Co-treatment of bortezomib with agents
that either induce autophagy or abrogate its inhibition
such as palbociclib reduces the efficacy of proteasome
inhibitors. In contrast, combined treatment with agents
that inhibit autophagy and/or lysosomal degradation
might act synergistically with proteasome inhibitors. The
clinical consequences are therefore twofold: When
combining proteasome inhibitors with other chemother-
apeutics, particular care must be taken. Co-treatment
with a chemotherapeutic agent might cause nutrient
starvation, inhibit the PI3K/AKT/mTOR pathway, acti-
vate AMPK signaling pathway, and induce ROS or ER
stress which could eventually lead to prosurvival autoph-
agy induction. Furthermore, co-treatment could impair
CDK4 activity which, as we have shown, prevents pro-
survival autophagy upon proteasome inhibition in MCL.
On the other hand, proteasome inhibitors can be com-
bined with approved therapeutics that block autophagy.
Chloroquine and its derivative hydroxychloroquine,
which have been initially FDA approved as antimalarial
drug, are currently repurposed to inhibit autophagy and
are well tolerated in clinical use [60]. Interestingly, a
phase 1 clinical trial including patients with relapsed/re-
fractory myeloma showed promising results for the com-
bination of bortezomib with the autophagy inhibitor
hydroxychloroquine corroborating our results [61]. More
importantly, there are several more potent and specific au-
tophagy inhibitors under preclinical investigation [62].
As we have shown here with the fatty acid synthase in-
hibitor orlistat, it is a highly interesting approach to
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investigate established compounds for their potential to
regulate autophagy. This approach of re-positioning con-
ventional drugs to target autophagy and induce cancer
cell death was already shown for several therapeutics
[63]. Orlistat might impair the autophagic machinery
due to a reduction in palmitate levels [43–45]. Our
group has previously shown that orlistat-induced cell
death in MCL is indeed palmitate-dependent [24]. Alter-
natively, there are recent reports showing that lipid
droplets and their components triglycerides are linked to
endoplasmic reticulum homeostasis and autophagy regu-
lation [64]. In line with this, another fatty acid synthase
inhibitor Cerulenin has also been shown to inhibit
autophagy due to lipid droplet downregulation [65]. Fur-
thermore, we observed that co-treatment of bortezomib
with Cerulenin potentiates cell death in a similar
manner as orlistat does (data not shown).
NOXA contains six lysine sites and is substrate for poly-
ubiquitination [56]. The only reported polyubiquitin
chains for NOXA are K11 or K48 linkages [36, 66]. Al-
though the K63 linkage has been shown to direct proteins
preferentially towards autophagy instead of proteasomal
degradation, all ubiquitin linkages including K11 and
K48 have been shown to be involved in autophagoso-
mal trafficking [67, 68]. Interestingly, our results show
that orlistat is more effective in potentiating proteaso-
mal inhibitor-mediated cell death and NOXA accu-
mulation as compared to autophagy inhibitors. Our
group previously demonstrated that orlistat interferes
with NOXA ubiquitination [24]. Polyubiquitination is
important for substrate selectivity of UPS as well as
ALP [57, 69]. Therefore, in addition to orlistat block-
ing the late steps of ALP process (Fig. 4a), orlistat
potentially impairs proteasomal degradation as well as
trafficking of NOXA protein to autophagy in parallel
and thus subsequently causing hyper-accumulation of
NOXA protein.
In addition to the aforementioned mechanisms, many
chemotherapeutics have shown to cause oxidative stress
[70]. Therefore, it might be a promising approach inves-
tigating concomitant autophagy induction as oxidative
stress regulates autophagy [71]. There is also growing
insight into the interaction between DNA damage re-
sponse and autophagy regulation [72]. It will be highly
interesting to investigate if standard therapy regimes like
R-CHOP could benefit from autophagy inhibitors.
Conclusion
Our data demonstrate for the first time that the high
CDK4 activity in MCL is a prerequisite for the response to
bortezomib therapy as well as for other compounds that
require stabilization of NOXA for efficient cell death in-
duction. We found out that the underlying molecular
mechanism is a mitigated autophagy due to high CDK4
activity, offering novel combination treatment strategies in
MCL and bortezomib-resistant cells. We show that
NOXA can be degraded by the autophagosome and that
blocking the residual autophagic activity combined with
proteasome inhibition leads to highly efficient cell death
in MCL due to super induction of NOXA protein.
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Additional file 1: Table S1. Sequences targeted by the siRNAs used for
gene silencing. (TIFF 883 kb)
Additional file 2: Figure S1. CDK4 inhibition by palbociclib treatment
inhibits RB1 phosphorylation. MCL cell lines Jeko-1 and Granta-519 were
treated with 300 nM and MCL cell line Mino with 100 nM palbociclib. After
16 h, proteins were analyzed by Western blot. (TIFF 360 kb)
Additional file 3: Figure S2. Knockdown of cyclin D1 and CDK4
antagonizes bortezomib-induced cell death. MCL cell line Jeko-1 was
transfected with siRNA targeting CCND1 and CDK4. Twenty-four hours
after transfection, protein expression was analyzed (right) and cells
were treated with 8 nM bortezomib. Cell death was assessed by
AnnexinV-PI staining 24 h post-treatment (left). Data represent means
± S.D. from three independent experiments. (TIFF 833 kb)
Additional file 4: Figure S3. Double knockdown of cyclin D1 and CDK4
antagonizes bortezomib-induced cell death similar to single knockdown
of CDK4. MCL cell line Mino was transfected with siRNA targeting CCND1,
CDK4, or both. Twenty-four hours after transfection, protein expression
was analyzed (right) and cells were treated with 8 nM bortezomib. Cell
death was assessed by AnnexinV-PI staining 24 h post-treatment (left).
Data represent means ± S.D. from three independent experiments.
(TIFF 903 kb)
Additional file 5: Figure S4. CDK4 inhibition antagonizes cell death
of NOXA inducing substances. MCL cell line Jeko-1 was pretreated
with 300 nM palbociclib for 16 h and subsequently co-treated with
either 8 nM carfilzomib, 40 μM orlistat, or 500 μM hydrogen peroxide. After
24 h treatment, cell death was assessed by AnnexinV-PI staining. Data
represent means ± S.D. from three independent experiments. (TIFF 950 kb)
Additional file 6: Figure S5. Inhibition CDK4 activity hardly alters NOXA
mRNA levels after proteasome inhibition. MCL cell line Mino was treated
with 100 nM and Granta-519 with 300 nM Palbociclib for 16 h and
subsequently co-treated with 8 nM bortezomib. After 8 h co-treatment
samples were taken and analyzed by real-time PCR. NOXA mRNA
expression was normalized to TBP. Data represent means ± SD from three
experiments. (TIFF 569 kb)
Additional file 7: Figure S6. Palbociclib-mediated antagonism on
bortezomib-induced cell death is not caused by alterations in cell cycle
distribution. MCL cell line Mino was transfected with siRNA targeting RB1
and treated with 100 nM palbociclib 24 h post-transfection. After 16 h,
cells were treated with 8 nM bortezomib. Twenty-four hours after
treatment, cell cycle distribution was measured by BrdU staining (left), cell
death was assessed by AnnexinV-PI staining (middle panel), and proteins
were analyzed by Western blot (right). Data represent means ± S.D. from
three independent experiments. (TIFF 802 kb)
Additional file 8: Figure S7. Palbociclib treatment induces autophagy
but not after a short treatment period. (A) MCL cell line Jeko-1 was
treated with 300 nM palbociclib for 24 h with or without 40 μM
hydroxychloroquine. After treatment, autophagic vesicles were measured
with Cyto-ID staining. (B) MCL cell line Mino was treated with 100 nM
palbociclib for 6 h. After treatment autophagic vesicles were measured with
Cyto-ID staining. (TIFF 1187 kb)
Additional file 9: Figure S8. Autophagy inhibitors counteract
palbociclib-mediated antagonism on bortezomib-induced cell death.
MCL cell line Jeko-1 was treated with 20 μM liensinine (left), 2 mM 3-MA
(left), or 10 μM Spautin-1 (right) with or without 300 nM palbociclib. After
16 h, cells were treated with 8 nM bortezomib for 24 h and analyzed by
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AnnexinV-PI staining to assess cell death. Data represent means ± S.D.
from three independent experiments. (TIFF 690 kb)
Additional file 10: Figure S9. Co-treatment of bortezomib with
autophagy inhibitors potentiates cell death induction. MCL cell line Rec-1
was pretreated with 20 μM liensinine, 120 μM hydroxychloroquine, or
5 mM 3-MA for 16 h and subsequently co-treated with 8 nM bortezomib.
After 24 h treatment, cell death was assessed by AnnexinV-PI staining.
Data represent means ± S.D. from three independent experiments.
(TIFF 725 kb)
Additional file 11: Figure S10. Synergistic cell death after proteasome
inhibition and simultaneous fatty acid inhibition is caspase dependent.
MCL cell line Jeko-1 was treated with 50 μM of the pan-caspase inhibitor
Z-VAD-FMK for 2 h subsequently treated with 7 nM bortezomib or
carfilzomib and co-treated with 15 μM orlistat. After 24 h, cell death was
assessed by AnnexinV-PI staining. Data represent means ± S.D. from three
experiments. (TIFF 774 kb)
Additional file 12: Figure S11. Combination of proteasome inhibition
and simultaneous fatty acid inhibition regulates mainly NOXA protein
levels and not PUMA, BAX, BAK, or MCL1. MCL cell line Jeko-1 was
treated with 7 nM bortezomib or carfilzomib and co-treated with 15 μM
orlistat. After 14 h, protein expression was analyzed by Western blot.
(TIFF 1502 kb)
Additional file 13: Figure S12. Proteasome inhibitors combined with
fatty acid inhibition induce synergistic cell death. MCL cell line Jeko-1
was treated with either five concentrations of carfilzomib or four
concentrations of bortezomib and co-treated with four concentrations of
orlistat (concentrations in the table). After 24 h, cell death was assessed
by AnnexinV-PI staining. Induced cell death was used as fractional effect
for determining the combination index (CI). (TIFF 1773 kb)
Additional file 14: Figure S13. NOXA protein contains a potential LIR
motif. The amino acid sequence DGFRRL at the position 29-34 in the
NOXA protein represents a potential LIR motif with the core consensus
sequence ((W/F/Y) XX (L/I/V)). The acidic amino acid is highlighted in red.
(TIFF 829 kb)
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